Evidence map›Paper›PMID 33428376›Full record

ArticleBiomacromolecules2021

Design of a PEGylated Antimicrobial Prodrug with Species-Specific Activation.

Meghan K O'Leary, Sabrina S Chen, Lars F Westblade, Christopher A Alabi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomacromolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Lectin-Targeted Prodrugs Activated byJournal of medicinal chemistry · 2022
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Meghan K O'LearyRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, 120 Olin Hall, Ithaca, New York 14853, United States.
Sabrina S ChenRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, 120 Olin Hall, Ithaca, New York 14853, United States.
Lars F WestbladeDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York 10065-4805, United States.
Christopher A AlabiRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, 120 Olin Hall, Ithaca, New York 14853, United States.ORCID 0000-0003-2654-018X
Cornell University · US

Funding

Acquisition of a Hybrid Quadrupole Time of Flight LC-MS/MS System for the CornellS10OD017992 · OD · CORNELL UNIVERSITY · PI ZHANG, SHENG · 2014 to 2014
$600k
Targeted Macromolecular Antimicrobial Prodrugs Against Pseudomonas AeruginosaR21AI154102 · NIAID · CORNELL UNIVERSITY · PI ALABI, CHRISTOPHER AKINLEYE · 2020 to 2021
$421k
NIAID NIH HHS R21 AI154102NIH HHS S10 OD017992
6 · The paper itself

Abstract

The rise of multidrug-resistant (MDR) "superbugs" has created an urgent need to develop new classes of antimicrobial agents to target these organisms. Oligothioetheramides (oligoTEAs) are a unique class of antimicrobial peptide (AMP) mimetics with one promising compound, BDT-4G, displaying potent activity against MDR

Indexed as

Anti-Infective AgentsProdrugsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesMicrobial Sensitivity TestsPolyethylene GlycolsPseudomonas aeruginosaSpecies SpecificityAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial Cationic PeptidesPolyethylene GlycolsProdrugs

Identifiers

PMID33428376
PMCPMC8270352
OpenAlexW3119998089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.